Skip to main content
IRWD logo

IRWD · Ironwood Pharmaceuticals Inc · Webcasts, Transcripts & Audio

Track IRWD — free
$4.72 -0.06 (-1.34%) Play latest call Q3 2026 earnings call transcript
Market Cap
$767.33M
Shares
165.55M
Volume · Nov 19 912.12K Avg daily vol (3M) 2.1M

Ironwood Pharmaceuticals Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Ironwood Pharmaceuticals Inc (IRWD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-11-05
Ironwood Pharmaceuticals Inc (IRWD) Q3 2026 Earnings Call Transcript
Confident tone Linzess sales growth and guidance raise Apraglutide clinical development Commercial access and pricing
Revenue
$133.04M
▲ 9% YoY
Diluted EPS
$0.36
▲ 56.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-10
Ironwood Pharmaceuticals Inc (IRWD) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Ironwood Pharmaceuticals Inc (IRWD) Q2 2026 Earnings Call
Revenue
$113.04M
▲ 32.6% YoY
Diluted EPS
$0.31
▲ 121.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Ironwood Pharmaceuticals Inc (IRWD) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Ironwood Pharmaceuticals Inc (IRWD) Q1 2026 Earnings Call Transcript
Confident tone Apraglutide / SBS-IF opportunity Linzess commercial performance Pricing and gross-to-net dynamics
Revenue
$106.51M
▲ 158.9% YoY
Diluted EPS
$0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Ironwood Pharmaceuticals Inc (IRWD) Q4 2025 Earnings Call Transcript
Confident tone LINZESS commercial performance and market leadership Aproglutide STARS II confirmatory Phase III trial 2026 financial guidance and EBITDA growth
Revenue
$47.71M
▼ 47.3% YoY
Diluted EPS
$-0.01
▼ 200% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q4
2025-02-27
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Transcript
Positive tone Short bowel syndrome commercial opportunity Apraglutide NDA progress LINZESS franchise
Revenue
$90.55M
▼ 23% YoY
Diluted EPS
$0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Transcript
Positive tone LINZESS commercial performance Apraglutide NDA and launch Profit and cash flow maximization
Revenue
$91.59M
▼ 19.5% YoY
Diluted EPS
$0.02
▼ 77.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Transcript
Positive tone LINZESS prescription demand Apraglutide NDA submission Apraglutide clinical profile and STARS Phase 3
Revenue
$94.40M
▼ 12.1% YoY
Diluted EPS
$-0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Ironwood Pharmaceuticals Inc (IRWD) Q1 2024 Earnings Call Transcript
Confident tone Apraglutide Phase III STARS results LINZESS commercial performance 2024 financial guidance and one-time adjustment
Revenue
$74.88M
▼ 28% YoY
Diluted EPS
$-0.03
▼ 112% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Ironwood Pharmaceuticals Inc (IRWD) Q4 2023 Earnings Call Transcript
Confident tone Apraglutide / STARS Phase 3 in short bowel syndrome LINZESS commercial performance Pipeline catalysts and upcoming data readouts
Revenue
$117.55M
▲ 9.7% YoY
Diluted EPS
$-0.01
▼ 103.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Ironwood Pharmaceuticals Inc (IRWD) Q3 2023 Earnings Call Transcript
Revenue
$113.74M
▲ 4.7% YoY
Diluted EPS
$0.09
▼ 67.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Ironwood Pharmaceuticals Inc (IRWD) Q2 2023 Earnings Call Transcript
Revenue
$107.38M
▲ 10.4% YoY
Diluted EPS
$-6.84
▼ 3357.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-22
Ironwood Pharmaceuticals Inc (IRWD) Q1 2023 Earnings Call Transcript
Revenue
$104.06M
▲ 6.7% YoY
Diluted EPS
$0.25
▲ 19% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-16
Ironwood Pharmaceuticals Inc (IRWD) Q4 2022 Earnings Call Transcript
Revenue
$107.20M
▼ 8.5% YoY
Diluted EPS
$0.27
▲ 8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Ironwood Pharmaceuticals Inc (IRWD) Q3 2022 Earnings Call Transcript
Revenue
$108.64M
▲ 4.7% YoY
Diluted EPS
$0.28
▼ 17.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Ironwood Pharmaceuticals Inc (IRWD) Q2 2022 Earnings Call Transcript
Revenue
$97.23M
▼ 6.5% YoY
Diluted EPS
$0.21
▼ 91.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Ironwood Pharmaceuticals Inc (IRWD) Q1 2022 Earnings Call Transcript
Revenue
$97.53M
▲ 9.8% YoY
Diluted EPS
$0.21
▼ 16% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-17
Ironwood Pharmaceuticals Inc (IRWD) Q4 2021 Earnings Call Transcript
Revenue
$117.13M
▲ 0.4% YoY
Diluted EPS
$0.25
▼ 7.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Ironwood Pharmaceuticals Inc (IRWD) Q3 2021 Earnings Call Transcript
Revenue
$103.75M
▲ 0.3% YoY
Diluted EPS
$0.34
▲ 61.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Ironwood Pharmaceuticals Inc (IRWD) Q2 2021 Earnings Call Transcript
Revenue
$104.03M
▲ 16.3% YoY
Diluted EPS
$2.39
▲ 1393.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Ironwood Pharmaceuticals Inc (IRWD) Q1 2021 Earnings Call Transcript
Revenue
$88.84M
▲ 11.1% YoY
Diluted EPS
$0.25
▲ 1150% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-17
Ironwood Pharmaceuticals Inc (IRWD) Q4 2020 Earnings Call Transcript
Revenue
$116.68M
▼ 7.6% YoY
Diluted EPS
$0.27
▼ 10% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Transcript
Revenue
$103.47M
▼ 21.1% YoY
Diluted EPS
$0.21
▲ 61.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Ironwood Pharmaceuticals Inc (IRWD) Q2 2020 Earnings Call Transcript
Revenue
$89.43M
▼ 12.5% YoY
Diluted EPS
$0.16
▲ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Ironwood Pharmaceuticals Inc (IRWD) Q1 2020 Earnings Call Transcript
Revenue
$79.94M
▲ 16.3% YoY
Diluted EPS
$0.02
Gross margin
97.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–26 of 26 webcasts
Key facts CIK 1446847 CUSIP 46333X108 13F (30d) 243 filings 221 filers Visit website Investor relations